Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
The P/B ratio is N/A as of 2026-10-06T16:38:25.083Z.
Calculation as of: 2026-10-06T16:38:25.083Z.
Quote observation: 2026-10-06T16:30:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2d3a9198413857e44d8ff08287218970dc762668c083e85858692cc7a401d48f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
N/A
Neonc Technologies Holdings, Inc.
Market Cap
$78.05M
PB Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$79.45M
PB Ratio
18.18
TTM Avg
11.08
3Y Avg
3.95
5Y Avg
2.91
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neonc Technologies Holdings, Inc. (NTHI) | $78.05M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $78.14M | 1.99 | 1.39 | 2.18 | 2.79 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.45M | 18.18 | 11.08 | 3.95 | 2.91 |
| Sera Prognostics, Inc. (SERA)vs › | $79.82M | 1.34 | 1.62 | 2.46 | 1.81 |
| Citius Oncology, Inc. (CTOR)vs › | $81.81M | 2.03 | 1.96 | 4.96 | 4.96 |
| Outset Medical, Inc. (OM)vs › | $76.13M | 0.79 | 0.74 | 1.03 | 2.24 |
| SkinHealth Systems Inc. (SKIN)vs › | $75.91M | 1.37 | 2.12 | 3.52 | 8.69 |
| Hyperfine, Inc. (HYPR)vs › | $75.36M | 2.05 | 3.13 | 1.86 | 1.54 |
| Nutriband Inc. (NTRB)vs › | $82.05M | 15.41 | 7.85 | 7.01 | 5.52 |
| MediciNova, Inc. (MNOV)vs › | $82.45M | 2.21 | 1.76 | 1.49 | 1.52 |
P/B Ratio
N/A
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
